Monday Mar 25, 2019

Oral immunotherapies in MS a comparison of efficacy.

Associate Professor Tomas Kalincik (University of Melbourne, Australia) discusses oral immunotherapies, and what we know about the effects of these treatments on patient relapse and disability. Read the full paper here: https://jnnp.bmj.com/content/early/2019/01/12/jnnp-2018-319831

Copyright 2023 All rights reserved.

Version: 20241125